ArticleFrontiers in cell and developmental biology2021

Anti-Tumor Necrosis Factor Receptor 2 Antibody Combined With Anti-PD-L1 Therapy Exerts Robust Antitumor Effects in Breast Cancer.

Qiang Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.